Clinical trial NCT01119534: Comparative Efficacy of the Suppository Versus Guaiacol Suppository Versus Guaifenesin Syrup in Pediatric Patients With Cough Due the Infectious Origin
Official title: Comparative Efficacy of the Suppository Composed by Guaiacol, Eucalyptol, Menthol and Camphor Versus Guaiacol Suppository Versus Guaifenesin Syrup in Pediatric Patients With Cough Due the Infectious Origin
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Cough
Keywords: Cough treatment
Lead sponsor: Azidus Brasil
Sponsor class: INDUSTRY
First posted: 2010-05-07
Enrollment: 270
Sex: ALL
Minimum age (years): 2
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: It is believed that the suppository consisting of guaiacol, menthol, camphor and eucalyptol, by their pharmacological properties already established for each component, has the ability to reduce the signs and symptoms related to upper respiratory infections in a manner equivalent (not inferior) to medicine used as a comparator in this study and higher than the suppository containing only guaiacol concentration of 12.5 mg.


Eligibility criteria: Inclusion Criteria:

* Patients that parents or legal guardians agree to their participation in the study and agree on the terms proposed in the IC, signing it;
* Patients aged ≥ (greater than or equal to) 02 years and ≤ (less than or equal to) 6 years, 11 months and 29 days, of any ethnicity, class or social group.
* Patients with acute respiratory disease of upper respiratory viral diseases (URI);
* Patients with productive cough;
* Clinical picture of URI defined by the doctor that started less than 48 hours.

Exclusion Criteria:

* Patients being treated with antibiotics;
* Presence of clinical features of bacterial infection of the upper airways and / or pulmonary (acute bacterial sinusitis, pneumonia, etc.).
* Patients with non-productive cough;
* Treatment with immunosuppressive drugs;
* Presence of any medical condition that, according to the investigator, should prevent the patient from the study;
* Participation in clinical trials in the 12 months preceding the study, according to Resolution 251 (ANVISA), August 7, 1997, item III, sub-item J;
* Patients with serious diseases;
* Patients who require multidrug treatment;
* Presence of other concomitant pulmonary diseases
* History of hypersensitivity to drugs of the same pharmacological classes of substances under investigation;
* Patients with diseases that interfere with lung function, such as cerebral palsy or muscular atrophies;
* Patients under medication or supplement (eg physiotherapy) that may interfere with the cough;
* Patients with severe dysfunction of the hepatorenal function;
* Patients with x-ray of the chest or sinus compatible with picture of bacterial infection;
* Patients with blood cell count suggestive of bacterial infection;
* Changes in laboratory, clinical, physical and / or radiological agents that, judged by investigators, could compromise patient health or reliability of the data.

Primary outcomes:
measure: Improvement of cough of infectious origin.
timeFrame: 7 days of treatment.
Secondary outcomes:
measure: Analysis of parameters for the improvement of infectious cough.
timeFrame: 7 days of treatment.
Other outcomes:
Locations:
city: Valinhos
country: Brazil
facility: LAL Clínica Pesquisa e Desenvolvimento Ltda
state: SP
Study officials:
References: